| scholarly article | Q13442814 |
| P50 | author | Ming Tan | Q115232766 |
| P2093 | author name string | Xi Jiang | |
| P2860 | cites work | Goose parvovirus structural proteins expressed by recombinant baculoviruses self-assemble into virus-like particles with strong immunogenicity in goose | Q44413898 |
| Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial | Q45189946 | ||
| A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge | Q45354931 | ||
| Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development | Q45358131 | ||
| Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope | Q45363890 | ||
| Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys | Q45387290 | ||
| Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope. | Q45396371 | ||
| Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge | Q45396589 | ||
| A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity | Q45409539 | ||
| Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults | Q45416013 | ||
| A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula | Q45519794 | ||
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
| Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. | Q45741599 | ||
| Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus | Q45750008 | ||
| A statewide assessment of the role of Norwalk virus in outbreaks of food-borne gastroenteritis | Q45839015 | ||
| Protective efficacy of virus-like particles for bluetongue disease | Q45880426 | ||
| Risk of intussusception after monovalent rotavirus vaccination | Q46186510 | ||
| Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry | Q46851930 | ||
| Rotavirus vaccines--balancing intussusception risks and health benefits | Q47119066 | ||
| A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults | Q47835936 | ||
| Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine | Q48004555 | ||
| The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection | Q49105055 | ||
| Universal influenza A vaccine: optimization of M2-based constructs | Q49115229 | ||
| Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies | Q49155216 | ||
| A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. | Q51525883 | ||
| Human hepatitis B vaccine from recombinant yeast | Q52850114 | ||
| Development of a vaccine marker technology: display of B cell epitopes on the surface of recombinant polyomavirus-like pentamers and capsoids induces peptide-specific antibodies in piglets after vaccination. | Q54451887 | ||
| Porcine circovirus type 2 (PCV2) viral components immunomodulate recall antigen responses | Q57207435 | ||
| Plant-derived vaccine protects target animals against a viral disease | Q73137252 | ||
| Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine | Q73389272 | ||
| Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat | Q73870954 | ||
| Perspectives of vaccination against hepatitis E | Q74389243 | ||
| Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines | Q95788790 | ||
| A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection | Q24631774 | ||
| Hepatitis C virus structural proteins assemble into viruslike particles in insect cells | Q27469539 | ||
| Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection | Q27477660 | ||
| Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 | Q27625236 | ||
| A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity | Q28257857 | ||
| A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants | Q28278852 | ||
| A viral nanoparticle with dual function as an anthrax antitoxin and vaccine | Q28469319 | ||
| Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig | Q28743371 | ||
| M2e-based universal influenza A vaccine | Q30227479 | ||
| Influenza virus-like particles as pandemic vaccines | Q30227553 | ||
| Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. | Q30375784 | ||
| Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. | Q30375991 | ||
| Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes | Q30404415 | ||
| Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. | Q32180102 | ||
| A vaccine against nicotine for smoking cessation: a randomized controlled trial | Q33346321 | ||
| Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells | Q33351949 | ||
| Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies | Q33785841 | ||
| Immunization with a pentameric L1 fusion protein protects against papillomavirus infection | Q33853398 | ||
| Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus | Q33865400 | ||
| A universal influenza A vaccine based on the extracellular domain of the M2 protein | Q33875466 | ||
| Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes | Q33909134 | ||
| Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor | Q34000082 | ||
| Safety and efficacy of a recombinant hepatitis E vaccine | Q34002701 | ||
| Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus | Q34019891 | ||
| Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus | Q34045644 | ||
| Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection | Q34054427 | ||
| The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors | Q34123964 | ||
| A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts | Q34261339 | ||
| Virus-like particles of a fish nodavirus display a capsid subunit domain organization different from that of insect nodaviruses. | Q34339950 | ||
| Generation of a parvovirus B19 vaccine candidate | Q34355555 | ||
| Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | Q34415030 | ||
| Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates | Q34437852 | ||
| Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody Production | Q34485266 | ||
| Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle | Q34587965 | ||
| Norovirus P particle efficiently elicits innate, humoral and cellular immunity | Q34702360 | ||
| Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles | Q34724844 | ||
| Ebola virus-like particles protect from lethal Ebola virus infection | Q34792924 | ||
| Induction of a protective immune response against viral nervous necrosis in the European sea bass Dicentrarchus labrax by using betanodavirus virus-like particles | Q35101543 | ||
| Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice | Q35188476 | ||
| Safety and immunogenicity of a candidate parvovirus B19 vaccine | Q35268947 | ||
| A candidate dual vaccine against influenza and noroviruses | Q35301295 | ||
| Virus-like particles as HIV-1 vaccines | Q35918111 | ||
| Noroviral P particle: structure, function and applications in virus-host interaction | Q36429481 | ||
| Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein | Q36522565 | ||
| Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection | Q36636635 | ||
| Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles | Q36669184 | ||
| Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts | Q36678270 | ||
| Recombinant vaccine for canine parvovirus in dogs | Q36697229 | ||
| Polyvalent complexes for vaccine development | Q36792270 | ||
| Recombinant virus vaccine for bluetongue disease in sheep | Q36805280 | ||
| A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies | Q36889041 | ||
| Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines | Q36948876 | ||
| Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle | Q37038082 | ||
| Norovirus vaccine against experimental human Norwalk Virus illness | Q37144052 | ||
| Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. | Q37163704 | ||
| Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein | Q37335489 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| A dual vaccine candidate against norovirus and hepatitis E virus | Q37502688 | ||
| Prospects for prophylactic hepatitis C vaccines based on virus-like particles | Q37505405 | ||
| Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms | Q37547757 | ||
| From the circumsporozoite protein to the RTS, S/AS candidate vaccine | Q37608882 | ||
| VP6: A Candidate Rotavirus Vaccine | Q37777737 | ||
| Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design | Q37792984 | ||
| Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease | Q38081968 | ||
| SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier | Q38081973 | ||
| Virus-like particle-based human vaccines: quality assessment based on structural and functional properties | Q38152530 | ||
| Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animals | Q38320531 | ||
| Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice | Q39166925 | ||
| Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. | Q39272520 | ||
| Assembly and immunogenicity of coronavirus-like particles carrying infectious bronchitis virus M and S proteins | Q39338278 | ||
| A virus-like particle-based Epstein-Barr virus vaccine | Q39458965 | ||
| Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen | Q39490917 | ||
| Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery | Q39588697 | ||
| Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine | Q39681193 | ||
| Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. | Q40099683 | ||
| Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. | Q40205403 | ||
| Virus-like particle-based countermeasures against Rift Valley fever virus | Q40254473 | ||
| Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice | Q40263422 | ||
| Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. | Q40280642 | ||
| Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections | Q40511451 | ||
| Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice | Q40525158 | ||
| Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis | Q42014293 | ||
| Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. | Q42047559 | ||
| Intussusception risk after rotavirus vaccination in U.S. infants | Q42232989 | ||
| Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine | Q42233344 | ||
| Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge | Q42250200 | ||
| Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. | Q42250611 | ||
| Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease | Q42268317 | ||
| Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle. | Q42284484 | ||
| Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial | Q42754531 | ||
| Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). | Q43671434 | ||
| A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors | Q43831558 | ||
| Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. | Q44079611 | ||
| Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV. | Q44176217 | ||
| Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. | Q44201038 | ||
| Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs | Q44317220 | ||
| A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. | Q44400704 | ||
| Chimeric calicivirus-like particles elicit specific immune responses in pigs. | Q44405819 | ||
| P304 | page(s) | 24-33 | |
| P577 | publication date | 2014-03-21 | |
| P1433 | published in | Current opinion in virology | Q26842394 |
| P1476 | title | Subviral particle as vaccine and vaccine platform | |
| P478 | volume | 6 |
| Q64933402 | A Recombinant Subviral Particle-Based Vaccine Protects Magpie (Pica pica) Against West Nile Virus Infection. |
| Q40093469 | Adjuvant formulations for virus-like particle (VLP) based vaccines |
| Q91576751 | Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine Platform |
| Q34064413 | Branched-linear and agglomerate protein polymers as vaccine platforms |
| Q63246352 | Construction and Immunogenicity of Novel Chimeric Virus-Like Particles Bearing Antigens of Infectious Bronchitis Virus and Newcastle Disease Virus |
| Q37665363 | Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle. |
| Q93099494 | Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha |
| Q48103866 | Establishment of a yeast-based VLP platform for antigen presentation. |
| Q27320566 | Fusion to a homo-oligomeric scaffold allows cryo-EM analysis of a small protein |
| Q91872608 | Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity |
| Q30234848 | Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy |
| Q27013018 | Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins |
| Q90397530 | Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2 |
| Q90231715 | Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development |
| Q27493140 | Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses |
| Q38819439 | Recent advancements in combination subunit vaccine development |
| Q38818912 | Viruses, Artificial Viruses and Virus-Based Structures for Biomedical Applications |
Search more.